Aeolus Pharmaceuticals, Inc. (AOLS)

Aeolus Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Jun 30, 2017	Sep 30, 2016	Sep 30, 2015	Sep 30, 2014	Sep 30, 2013	Sep 30, 2012
Revenue	0.77	2.08	3.11	9.63	3.93	7.29
Revenue Growth (YoY)	-68.71%	-33.27%	-67.70%	145.19%	-46.14%	51.28%
Cost of Revenue	2.49	2.88	3.51	6.97	3.36	6.47
Gross Profit	-1.72	-0.81	-0.4	2.67	0.57	0.83
Selling, General & Admin	2.37	2.47	2.23	2.75	3.27	3.2
Operating Expenses	2.37	2.47	2.23	2.75	3.27	3.2
Operating Income	-4.09	-3.27	-2.63	-0.08	-2.7	-2.37
Interest Expense	-	-0.29	-0	-	-	-
Other Non Operating Income (Expenses)	-	-	-	-	-0.51	4.07
EBT Excluding Unusual Items	-4.09	-3.56	-2.63	-0.08	-3.21	1.7
Pretax Income	-4.09	-3.56	-2.63	-0.08	-3.21	1.7
Net Income	-4.09	-3.56	-2.63	-0.08	-3.21	1.7
Preferred Dividends & Other Adjustments	-	2.49	-	-	-	0.84
Net Income to Common	-4.09	-6.04	-2.63	-0.08	-3.21	0.86
Net Income Growth	-	-	-	-	-	467.89%
Shares Outstanding (Basic)	152	149	136	135	107	62
Shares Outstanding (Diluted)	152	149	136	135	107	71
Shares Change (YoY)	5.16%	9.41%	0.90%	26.38%	49.99%	-17.26%
EPS (Basic)	-0.03	-0.04	-0.02	-0.00	-0.03	0.01
EPS (Diluted)	-0.03	-0.04	-0.02	-0.00	-0.03	-0.03
Free Cash Flow	-3.35	-3.11	-2.44	0.32	-2.97	-0.88
Free Cash Flow Per Share	-0.02	-0.02	-0.02	0.00	-0.03	-0.01
Gross Margin	-223.22%	-38.78%	-12.79%	27.67%	14.46%	11.31%
Operating Margin	-531.00%	-157.66%	-84.41%	-0.83%	-68.69%	-32.51%
Profit Margin	-531.00%	-291.14%	-84.47%	-0.83%	-81.67%	11.74%
Free Cash Flow Margin	-434.89%	-149.76%	-78.53%	3.35%	-75.61%	-12.05%
EBITDA	-	-	-	-0.07	-2.69	-2.36
EBITDA Margin	-	-	-	-0.77%	-68.53%	-32.41%
D&A For EBITDA	-	-	-	0.01	0.01	0.01
EBIT	-4.09	-3.27	-2.63	-0.08	-2.7	-2.37
EBIT Margin	-	-157.66%	-84.41%	-0.83%	-68.69%	-32.51%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.